GLAXOSMITHKLINE PHARMACEUTICALS LTD.

GlaxoSmithKline Pharmaceuticals Ltd has announced a trading window closure for its shares. This restriction on buying or selling company shares will be in effect from Thursday, October 1, 2026, until 48 hours after the declaration of the Un-audited Financial Results for the second quarter and half year ended September 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, aimed at preventing potential insider trading.

GlaxoSmithKline Pharmaceuticals Ltd has responded to an inquiry regarding a significant increase in trading volume. The company stated that it has made all necessary disclosures as per SEBI regulations and has not withheld any material information. They clarified that the surge in volume is purely market-driven and reiterated their commitment to complying with listing regulations and informing the stock exchange of any price-sensitive information.

GlaxoSmithKline Pharmaceuticals Ltd has received an intimation under Section 143(1) of the Income Tax Act, resulting in a tax refund of ₹4.99 Crores for the Assessment Year 2025-2026. The refund was credited to the company's bank account on August 18, 2026. This refund will be accounted for in the 'Tax Paid Assets' account on the company's balance sheet. No violations or contraventions were alleged.

GlaxoSmithKline Pharmaceuticals Ltd has received a final order from the ACIT Cir 7(1)(1) confirming a refund of ₹52 crores. This refund is post an order from the CIT-Appeal for the assessment year 1984-85. The company will credit an interest income of ₹42.09 crores on this refund to its Profit & Loss account. The demand liability associated with this order was ₹23.21 crores.

GlaxoSmithKline Pharmaceuticals Limited announced the re-appointment of Mr. Bhushan Akshikar as Managing Director for a term of two years, effective December 1, 2026. The Board of Directors also approved the un-audited standalone and consolidated financial results for the first quarter ended June 30, 2026. Additionally, Mr. Subesh Williams stepped down as Non-Executive Director, and Ms. Karine J F Natland will be appointed as a Non-Executive Director. The company reported revenue from operations of ₹92442 Lakhs for the quarter ended June 30, 2026.

GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Key management changes were also noted: Mr. Subesh Williams stepped down as Non-Executive Director, and Ms. Karine J F Natland is appointed as Non-Executive Director. Additionally, Mr. Bhushan Akshikar has been re-appointed as Managing Director for a term of two years effective December 1, 2026. The company reported Revenue from operations of ₹92,442 Lakhs and Other income of ₹6,163 Lakhs for the quarter ended June 30, 2026.

GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. Key management changes include the stepping down of Non-Executive Director Mr. Subesh Williams and the appointment of Ms. Karine J F Natland as a Non-Executive Director. Additionally, Mr. Bhushan Akshikar has been re-appointed as Managing Director for a term of two years effective December 1, 2026. The company reported revenue from operations of ₹92,442 Lakhs and other income of ₹6,163 Lakhs for the quarter.

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported strong financial results for the first quarter ended June 30, 2026. Revenue increased by 15% year-on-year to INR 924 crores, while Profit After Tax (PAT) surged by 24% to INR 253 crores. EBITDA margins stood at 32%. The company highlighted growth across its General Medicines, Respiratory, and Vaccines portfolios, with key brands like Augmentin and Nucala showing strong performance. The Oncology business also saw significant growth. GSK India is preparing for upcoming launches, including Blenrep and Arexvy, and has strengthened its supply chain resilience.

GlaxoSmithKline Pharmaceuticals Ltd announced the outcome of its Board Meeting held on August 3, 2026. The Board approved the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026, along with the Limited Review Report. Key management changes were also noted: Mr. Subesh Williams stepped down as Non-Executive Director, Ms. Karine J F Natland was appointed as Non-Executive Director, and Mr. Bhushan Akshikar was re-appointed as Managing Director for a two-year term starting December 1, 2026. The meeting commenced at 1:00 PM and concluded at 3:35 PM.

GlaxoSmithKline Pharmaceuticals delivered a clean double-digit growth quarter. On a consolidated basis — the primary lens, as it strips out intra-group flows — Q1 FY27 revenue rose 16.6% YoY to ₹938 Cr (₹805 Cr) and PAT rose 15.7% to ₹237 Cr (₹205 Cr), with EPS at ₹14.00 versus ₹12.10 a year ago. Both lines were down sequentially (revenue −5.7%, PAT −14.6% off Q4's ₹995 Cr / ₹278 Cr), but Q4 is seasonally the company's strongest quarter and carried a peak ~35% operating margin, so the QoQ dip is a seasonality artifact rather than a slowdown; the YoY read is what matters and it is firmly positive. The standalone-vs-consolidated gap is the one thing readers must not misread. Standalone PAT of ₹253 Cr is HIGHER than consolidated ₹237 Cr and shows a flattering +23.8% YoY — but that is inflated by an ₹18 Cr dividend from 100%-owned subsidiary Biddle Sawyer sitting in standalone other income (₹61.6 Cr vs ₹43.8 Cr consolidated). That dividend eliminates on consolidation, where the subsidiary instead contributes only its own ₹1.84 Cr profit, so consolidated +15.7% is the true underlying growth. There were no exceptional items in either the current or year-ago quarter, so raw and adjusted growth are the same. On margins, operating margin was ~31.5%, essentially flat versus 31.2% a year ago but well below Q4's ~35.3%; consolidated net margin edged up to 25.3% from 24.2% YoY, helped by a lower effective tax charge. The margin bridge is unremarkable — this was a topline-led quarter, driven by the base business normalising after last year's supply disruptions rather than by cost leverage. Against the bar we set in our pre-result preview, the print beats on the bottom line and lands mid-range on the top: revenue of ₹938 Cr fell inside the ₹900–950 Cr we expected, PAT growth of ~16% cleared the 6–10% YoY we flagged, but EBITDA margin of ~31.5% undershot the 33–35% band we looked for — a Q4-to-Q1 seasonal give-back, not a structural erosion. There is no public Street consensus for this quarter (coverage is thin; Motilal Oswal's ₹2,170 target frames the specialty thesis but sets no Q1 estimate). Versus management's own framing on the February concall — a long-term ambition to double revenue to ₹8,000 Cr over 5–7 years at 12–14% annual growth — this quarter's 16.6% runs comfortably ahead of that band, supporting the confident tone management carried into FY27; the company gives no formal near-term revenue or margin guidance. Of the watch items we flagged, the ₹3.54 Cr NPPA demand notice (June) is immaterial against a ₹938 Cr topline and did not dent the print; the FY26 annual report/AGM cleared in June with a ₹57/share final dividend. Alongside results the board re-appointed MD Bhushan Akshikar for two years from 1 December 2026, while non-executive director Subesh Williams resigned and Karine Natland (SVP APAC, GSK General Medicines) was named to replace him — continuity at the top with a stronger specialty-strategy link on the board. No management press release accompanied the numbers.